Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
3.37M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
382K
-
Shares change
-
-661K
-
Total reported value, excl. options
-
$1.23M
-
Value change
-
-$1.79M
-
Number of buys
-
5
-
Number of sells
-
-5
-
Price
-
$3.22
Significant Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q4 2024
20 filings reported holding CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value as of Q4 2024.
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 382K shares
of 3.37M outstanding shares and own 11.34% of the company stock.
Largest 10 shareholders include TYNDALL CAPITAL PARTNERS L P (165K shares), Siren, L.L.C. (116K shares), GEODE CAPITAL MANAGEMENT, LLC (31.8K shares), VANGUARD GROUP INC (23.5K shares), BlackRock, Inc. (16.8K shares), RENAISSANCE TECHNOLOGIES LLC (10.6K shares), UBS Group AG (9.67K shares), FMR LLC (4.74K shares), Tower Research Capital LLC (TRC) (2.44K shares), and MORGAN STANLEY (649 shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.